Gijtenbeek RGP, et al. Treatment tolerance and survival in elderly patients with stage IV non-small cell lung cancer (NSCLC). P4658. ERS 2019, 30 sept, Madrid, Spanje.
FLAURA2 toont overlevingsvoordeel van osimertinib plus chemotherapie
dec 2025 | Longoncologie